Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030388 | 0.87 | SIGMAR1 (0.60) | NSD2BCHEACHENPC1RAB9A | |
| SCHEMBL4034244 | 0.85 | NSD2 (0.54) | NSD2BCHEACHENPC1RAB9A | |
| SCHEMBL5118098 | 0.82 | NSD2 (0.63) | NSD2NPC1RAB9AKMT2ASIGMAR1 | |
| SCHEMBL19002498 | 0.81 | NSD2 (0.56) | NSD2NPC1RAB9AKMT2ASIGMAR1 | |
| SCHEMBL19049393 | 0.78 | NSD2 (0.58) | NSD2NPC1RAB9AKMT2ASIGMAR1 | |
| SCHEMBL5317577 | 0.75 | NSD2 (0.61) | NSD2NPC1KMT2ASIGMAR1TMEM97 | |
| SCHEMBL7114056 | 0.75 | RAB9A (0.58) | BCHEACHENPC1RAB9AKMT2A | |
| SCHEMBL4040827 | 0.74 | BDKRB1 (0.66) | NSD2BCHEACHERAB9APOLB | |
| SCHEMBL24827589 | 0.74 | NSD2 (0.55) | NSD2NPC1RAB9AKMT2ASIGMAR1 | |
| SCHEMBL19002504 | 0.74 | NSD2 (0.55) | NSD2NPC1RAB9AKMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | NSD2 2965/4885BCHE 3422/4885ACHE 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.